-
If you have any patients who use 28-day packages of Nortrel 7/7/7 oral contraceptives (OCs), be sure your clinic has initiated its patient notification plan following the July 9, 2003, voluntary recall issued by the pills manufacturer, Barr Laboratories of Pomona, NY.
-
The word is getting out about emergency contraception (EC). A just-released national survey reports that two-thirds of women ages 18-44 are aware that there is something a woman can do to prevent pregnancy in the few days following sexual intercourse.
-
Findings from a new Australian study indicate that use of modern, low-dose oral contraceptives (OCs) containing 50 mcg estrogen or less do not appear to appreciably raise the risk of ischemic stroke in healthy women.
-
Just-published papers in the Journal of the American Medical Association add to heightened concern regarding hormone therapy (HT).
-
The next patient in your exam room is a 32-year-old woman with type 2 (adult onset) diabetes. While she is obese, she does not smoke, and her chart shows no evidence of hypertension, nephropathy, or retinopathy. What birth control options can you offer her?
-
New video reviews teen birth control options; NAMS issues revised menopause guidelines
-
-
The long-awaited JNC-7 report was recently published in summary form; a more comprehensive manuscript will be forthcoming. JNC-7 takes into account many of the randomized controlled trials dealing with hypertension published over the past few years, and thus, is very much up to date. Some highlights of the report are as follows.
-
Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension; Tazarotene Cream in the Treatment of Psoriasis; Antihyperglycemic Effect of Oolong Tea in Type 2 Diabetes
-
This is the first study to convincingly demonstrate a strong dose-dependent relationship between increasing weight and increasing symptoms of gastroesophageal reflux.
